GoodCell (“LifeVault Bio”), the company decoding human health to extend and improve the quality of life through technology powered by science, today announced that it has raised $17.9 million in a preferred equity round. GoodCell intends to use this latest funding to support the company’s IP for detecting and monitoring accumulated genetic variation within blood cells. Financing will also help advance the company’s big data analytics platform to validate novel applications for its health tracking and risk identification solutions through GoodCell Diagnostics and GoodCell’s personal biobanking service.